A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SBLOF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.96 Med: 3.6 Max: 55.88
Current: 4.14
During the past 13 years, the highest Debt-to-EBITDA Ratio of Shin Nippon Biomedical Laboratories was 55.88. The lowest was 0.96. And the median was 3.60.
SBLOF's Debt-to-EBITDA is ranked worse than 74.11% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.29
vs SBLOF: 4.14
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Shin Nippon Biomedical Laboratories Debt-to-EBITDA Related Terms
Shin Nippon Biomedical Laboratories Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBLOF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Shin Nippon Biomedical Laboratories (SBLOF) has a Debt-to-EBITDA of 1.47 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shin Nippon Biomedical Laboratories. This is 59% below median its historical median of 3.60. Over the past decade, Shin Nippon Biomedical Laboratories' Debt-to-EBITDA has ranged from 0.96 to 55.88. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #83 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 74.1%.
Is Shin Nippon Biomedical Laboratories' Debt-to-EBITDA too high?
Shin Nippon Biomedical Laboratories' current Debt-to-EBITDA of 1.47 is 59% below median its 10-year median of 3.60. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 55.88. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.29. Shin Nippon Biomedical Laboratories' value of 1.47 is 35.8% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #83 out of 112 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #83 out of 112 companies for Debt-to-EBITDA. This places Shin Nippon Biomedical Laboratories in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. Shin Nippon Biomedical Laboratories' value of 1.47 is 35.8% below this benchmark. Historically, Shin Nippon Biomedical Laboratories' own Debt-to-EBITDA has ranged from 0.96 to 55.88 over the past decade. While the company's 10-year median is 3.60 vs. the industry median of 2.29, Shin Nippon Biomedical Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.29, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current Debt-to-EBITDA of 1.47 is 35.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shin Nippon Biomedical Laboratories. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current Debt-to-EBITDA is 1.47, which is 59% below median its own 10-year median of 3.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Debt-to-EBITDA of 1.47. The stock's GF Value™ is $12.76, compared to a current price of $9.16 — trading 28.2% below its estimated fair value. The current Debt-to-EBITDA is 1.47, which is 59% below median its 10-year median of 3.60 and 35.8% below the Medical Diagnostics & Research industry median of 2.29. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Debt-to-EBITDA is 1.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 28.2% below its estimated GF Value™ of $12.76.
Key valuation signals for SBLOF:
Debt-to-EBITDA: 1.47 (59% below median its 10-year median of 3.60)
GF Value™: $12.76 vs. price of $9.16 (28.2% below fair value)
Industry Position: 35.8% below the Medical Diagnostics & Research median (#83 of 112)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score
Get the complete analysis for SBLOF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
